Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Recruiting · NCT06518005 · Registry updated 2024-12-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crigler-Najjar syndrome, Nutritional and Metabolic Diseases, hereditary disease, hereditary hyperbilirubinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 2 | 2024-12-03 | NCT06518005 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genethon | 6 |
| Hansa Biopharma AB | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hopital Antoine Beclere | Clamart | France | 3 |